Vitiligo affects an estimated 28.5 million people worldwide, spanning every age group, sex, and ethnic background. The global lifetime prevalence sits at roughly 0.36% when diagnosed by a physician, though self-reported rates push that closer to 0.55%, suggesting many cases go formally undiagnosed. While no population is immune, certain groups carry a notably higher burden than others.
Prevalence Across Ethnic Groups
Vitiligo occurs in every racial and ethnic population, but not at equal rates. A large U.S. study published in JAMA Dermatology found that Asian American and Hispanic/Latino patients were diagnosed at roughly twice the rate of White patients. The age-adjusted incidence broke down like this:
- Asian American: 41.2 per 100,000 person-years
- Hispanic/Latino: 37.3 per 100,000
- Black: 29.6 per 100,000
- White: 18.7 per 100,000
Prevalence followed a similar pattern. Hispanic/Latino patients had the highest at 0.29%, followed by Asian American patients at 0.27%, Black patients at 0.22%, and White patients at 0.13%. These numbers reflect diagnosed cases, and the gap may partly reflect the fact that vitiligo is more visually apparent on darker skin, prompting more people to seek a diagnosis. Racial and ethnic minority populations also tend to report a greater impact on quality of life, likely because the contrast between affected and unaffected skin is more visible.
Globally, central Europe and south Asia report the highest lifetime prevalence, each at about 0.52% of the general population.
Age of Onset
About half of all vitiligo cases begin before age 20, and incidence generally decreases with age. That said, vitiligo can appear at any point in life. The average age of onset tends to differ between men and women: roughly 19 years for males and 24 years for females.
The type of vitiligo also matters. Segmental vitiligo, which affects only one side or area of the body, tends to appear much earlier, with a mean onset around age 14. Non-segmental vitiligo, the more common form (accounting for about 65% of cases), typically develops later, with an average onset around age 32. Non-segmental vitiligo is the type most people picture: roughly symmetrical white patches that can appear on both sides of the body and expand over time.
Men and Women Are Affected Equally
Vitiligo does not favor one sex over the other. Large studies from the Middle East, Africa, and other regions consistently show similar prevalence between males and females. Women do tend to seek treatment more often, which can create the impression of a female skew in clinical settings, but the underlying rate of the condition is the same. Quality-of-life scores, including standardized measures of how much a skin condition disrupts daily life, also show no significant difference between men and women with vitiligo.
The Role of Family History
Genetics play a clear role, though vitiligo doesn’t follow a simple inheritance pattern. About 20% of people with vitiligo have at least one first-degree relative (a parent, sibling, or child) who also has the condition. Children of someone with vitiligo face the highest relative risk, roughly 36 times that of the general population. Siblings carry about 12 times the risk, and parents about 7 times.
These numbers sound dramatic, but context matters. Because the baseline prevalence is low (under 1%), even a 36-fold increase in risk still means most children of a parent with vitiligo will never develop it. The condition involves multiple genes interacting with environmental triggers, not a single inherited mutation. Within families where vitiligo does cluster, the age of onset tends to be moderately correlated, meaning relatives often develop it around similar life stages.
Links to Other Autoimmune Conditions
Vitiligo is an autoimmune condition, meaning the immune system mistakenly attacks the cells that produce skin pigment. That same immune tendency raises the risk of other autoimmune problems. Roughly 27% of people with vitiligo have at least one additional autoimmune or autoinflammatory disease.
Thyroid disease is by far the most common overlap, affecting about 16% of vitiligo patients. This includes both overactive and underactive thyroid conditions driven by immune dysfunction. After thyroid disease, the most frequently seen conditions are alopecia areata (patchy hair loss, in about 5% of patients), psoriasis (3.7%), and rheumatoid arthritis (3.7%). Type 1 diabetes, inflammatory bowel disease, and lupus also appear at elevated rates, though each individually affects only 1 to 2% of vitiligo patients.
If you have vitiligo, periodic thyroid screening is a practical step, since thyroid problems are common enough in this group to warrant attention even without symptoms.
Psychological and Social Impact
The effects of vitiligo extend well beyond the skin. About a quarter of patients in quality-of-life studies score in ranges that indicate poor mental health, particularly around self-image and social anxiety. The visibility of the condition drives much of this burden. People with patches on the face, hands, or other exposed areas tend to report higher distress than those whose vitiligo is easily covered by clothing.
Age and cultural context shape the experience significantly. Younger adults and adolescents often struggle more with the social dimensions, especially during a life stage where appearance feels central to identity. In communities where skin appearance carries strong social weight, the stigma can be particularly isolating. The emotional toll is real and measurable, and it affects people across every demographic group that vitiligo touches.